DexCom, Inc. (DXCM) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is...
DexCom, Inc.'s revenue increased 15.6% year over year, from $4.03B to $4.66B.
Net income increased 45.1% over the same period, from $576.2M to $836.3M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 713% in total.
Total debt decreased by 46.0% to $1.40B.
The debt-to-equity ratio stands at 0.51, indicating a moderate leverage profile.
Operating cash flow grew 45.6% to $1.44B.
DexCom, Inc. maintains a healthy net profit margin of 17.9%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $994.2M-1.0% | $134.6M | $593.8M | $152.0M | $199.5M | $6.35B | $2.59B | $1.98B |
| Q4 FY2024 | $1.11B+12.0% | $151.7M | $655.8M | $188.9M | $301.4M | $6.48B | $2.59B | $2.10B |
| Q1 FY2025 | $1.04B-7.0% | $105.4M | $589.0M | $133.7M | $183.8M | $6.75B | $2.58B | $2.27B |
| Q2 FY2025 | $1.16B+11.7% | $179.8M | $688.8M | $212.6M | $303.0M | $7.33B | $2.58B | $2.57B |
| Q3 FY2025 | $1.21B+4.5% | $283.8M | $731.4M | $242.5M | $659.9M | $7.50B | $2.58B | $2.73B |
| Q4 FY2025 | $1.26B+4.2% | $267.3M | $792.7M | $323.0M | $294.0M | $6.34B | $1.40B | $2.75B |
| Q1 FY2026 | $1.19B-5.4% | $199.5M | $750.3M | $255.3M | $525.6M | $6.63B | $1.38B | $2.96B |
| Q2 FY2026 | $1.31B+9.8% | $249.1M | $830.0M | $318.3M | $269.2M | $6.46B | $1.40B | $2.62B |
Balance Sheet Summary (Q2 FY2026)
DexCom, Inc. (DXCM) Financial Statements & Revenue History
DexCom, Inc. (DXCM) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry trading at $85.90 with a market capitalization of $32. This page provides 42 historical financial statements for DexCom, Inc., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, DexCom, Inc. reported revenue of $4.7 billion, representing 15.6% year-over-year growth. The net profit margin of 17.9% reflects strong profitability. The debt-to-equity ratio of 0.51 reflects moderate leverage.
DXCM Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows DexCom, Inc.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether DXCM is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track DXCM's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently DexCom, Inc. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of DXCM's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use DXCM Financial Data
Investors use DexCom, Inc.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare DXCM's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how DXCM's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View DXCM's financial health score, earnings, and pre-market pricing.
Financial data is sourced from DexCom, Inc.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.DXCM trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.